Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-25-038644
Filing Date
2025-05-02
Accepted
2025-05-01 21:09:08
Documents
15
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K ea0240523-10ka1_apimeds.htm   iXBRL 10-K/A 72679
2 CERTIFICATION ea024052301ex31-1_apimeds.htm EX-31.1 9548
3 CERTIFICATION ea024052301ex31-2_apimeds.htm EX-31.2 9560
  Complete submission text file 0001213900-25-038644.txt   294759

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE apus-20241231.xsd EX-101.SCH 3102
5 XBRL LABEL FILE apus-20241231_lab.xml EX-101.LAB 32651
6 XBRL PRESENTATION FILE apus-20241231_pre.xml EX-101.PRE 16929
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0240523-10ka1_apimeds_htm.xml XML 6525
Mailing Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525
Business Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525 609-751-4485
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-42545 | Film No.: 25905185
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)